NLE Neurosensory Nursing — Sensory Disorders of the Eye and EarStudy Notes

Understanding normal anatomy is essential to recognize pathology and anticipate patient needs. **THE EYE: Light Pathway and Structures** Light enters the eye through the cornea, a transparent dome that provides about 70% of the eye's focusing power. It then passes through the pupil, an opening in the iris whose diameter is controlled by sympathetic and parasympathetic fibers of CN III (oculomotor). The lens, sitting behind the iris, provides fine-tuning of focus through accommodation—the ciliary muscle contracts to thicken the lens for near vision. The focused light strikes the retina, a photosensitive tissue lining the back of the eye that converts light energy into neural signals. The optic nerve (CN II) carries these signals to the visual cortex in the occipital lobe. **Aqueous Humor and Intraocular Pressure (IOP)** The ciliary body continuously produces aqueous humor, a clear fluid that maintains the eye's shape and provides oxygen and nutrients to the lens and cornea. Normally 2–3 microliters per minute is produced and an equal amount drains through the trabecular meshwork (a spongy tissue in the drainage angle) and then through the canal of Schlemm into the systemic circulation. Normal IOP ranges from 10–21 mmHg. When drainage is impaired, IOP rises, potentially damaging the optic nerve head. **THE EAR: Three Divisions** The ear is divided into three parts: - **Outer ear:** The auricle (pinna) collects sound waves, which are funneled through the external auditory canal to the tympanic membrane (eardrum). - **Middle ear:** An air-filled space behind the tympanum containing three tiny bones (ossicles)—malleus, incus, and stapes—that transmit vibrations from the tympanum to the inner ear. The eustachian tube connects the middle ear to the nasopharynx and equalizes pressure. - **Inner ear:** Contains the cochlea (spiral-shaped structure with hair cells that convert vibration to neural signals) and the vestibular apparatus (semicircular canals and utricle/saccule), which sense balance and body position. The vestibulocochlear nerve (CN VIII) carries hearing and balance signals to the brain. **Hearing Classification** Hearing loss is categorized as conductive (problem in the outer or middle ear blocking sound transmission) or sensorineural (damage to the inner ear hair cells or CN VIII). This distinction guides treatment: conductive loss is often correctable (e.g., cerumen removal, surgery), whereas sensorineural loss is usually permanent and may require amplification or implantation.

**Definition and Pathophysiology** A cataract is an opacity (clouding or loss of transparency) of the lens that scatters and diffuses light, blurring or distorting vision. The lens normally contains about 65% water and is composed of lens protein that remains transparent throughout life. With aging, lens proteins denature and cross-link, causing opacification. Cataracts may be unilateral or bilateral. **Risk Factors and Causes** - **Age-related (most common):** Progressive opacity beginning in the cortex (cortical cataract) or nucleus (nuclear cataract) - **Metabolic:** Diabetes (osmotic changes from hyperglycemia cause lens swelling and opacification) - **Medications:** Long-term corticosteroid use (increases protein cross-linking) - **Trauma:** Direct lens injury or hyphema (blood in anterior chamber) - **Congenital:** Intrauterine infection (rubella), genetic conditions - **Radiation or UV exposure** **Clinical Manifestations** Cataracts develop gradually and painlessly over months to years: - **Blurred or hazy vision** that worsens with age - **Glare and halos around lights** (especially at night), worse in bright light - **Faded or yellowed color perception** (blues and purples appear duller) - **Difficulty with night driving and reading** - **Complaint of needing more light** for tasks - **Monocular diplopia** (double vision in one eye when lens opacity creates multiple focal points) On physical examination: - **Absent or diminished red reflex** (the reddish glow of the retina normally visible on ophthalmoscopy) - **Pupil appears cloudy, white, or gray** (depending on cataract density and location) - **No pain** (the lens is avascular and lacks nerve fibers) **Diagnosis** Ophthalmoscopy and slit-lamp examination reveal lens opacity; visual acuity testing quantifies vision loss. Cataracts are graded by density (mild, moderate, mature, hypermature) and location (cortical, nuclear, posterior subcapsular). **Treatment: Surgical Lens Extraction** Cataract surgery is **elective**, performed when the cataract interferes significantly with the patient's activities of daily living or visual needs. It is one of the most commonly performed surgeries in the Philippines and worldwide. **Surgical Approach:** - **Phacoemulsification (most common):** An ultrasonic probe emulsifies the clouded lens nucleus, which is then aspirated through a small incision (2.2–2.75 mm). A foldable intraocular lens (IOL) is inserted to replace the lens function. Typically an outpatient procedure under topical anesthesia (drops). - **Extracapsular extraction:** The entire lens is removed through a larger incision; less common now but may be used for very dense nuclei. - **Intracapsular extraction:** The entire lens and capsule are removed; rarely used. - **IOL placement:** Most patients receive a monofocal IOL set for distance vision; some undergo monovision surgery or receive premium IOLs (multifocal, toric for astigmatism) to reduce dependence on glasses. **Preoperative Nursing Considerations** - Ensure **informed consent** and explain the procedure, expected outcomes, and realistic visual recovery (often takes 4–6 weeks for stable vision). - **Dilate the pupil** with mydriatic drops (tropicamide, phenylephrine) as ordered; document baseline visual acuity. - **NPO status** typically 6 hours (patient may receive IV sedation). - **Administer prophylactic topical antibiotics** (e.g., fluoroquinolone drops, e.g., moxifloxacin) 3 times the day before and morning of surgery. - **Assess for allergy to iodine** — many surgeons use iodine-based antiseptic (povidone-iodine) for surgical prep. - **Counsel on expectations:** Vision improves gradually; glasses or contact lenses may be needed for full correction; the unoperated eye may become more bothersome if a large vision difference develops. **Postoperative Nursing Care and IOP Precautions (CRITICAL)** The primary focus is **preventing increased intraocular pressure (IOP)** and infection, as both threaten the surgical outcome and can damage the optic nerve head. **Activities and Behaviors to Avoid:** - **No bending at the waist or stooping** (Valsalva increases IOP) - **No heavy lifting** (>5–10 lbs, depending on surgeon) for 4–6 weeks - **Avoid straining at stool** — stool softeners or mild laxatives prescribed - **No forceful coughing or sneezing** (if sneezing imminent, open mouth to prevent Valsalva) - **No sleeping on the operative side** for at least 1–2 weeks (risk of pressure on the eye) - **Avoid rapid head movements and eye strain** - **No rubbing or pressing on the eye** **Eye Protection and Hygiene:** - **Wear an opaque eye shield or patch** for 1 night after surgery; continue wearing it at night for 1–2 weeks to prevent accidental trauma during sleep. - **Dark glasses worn during the day** for comfort (the dilated pupil is photosensitive for a few days). - **Avoid dusty or smoky environments** for 1–2 weeks; keep the surgical eye clean but do not let tap water directly contact it (risk of bacteria). - **No swimming or hot tubs** for 1–2 weeks until the incision is fully sealed. **Medication Instillation:** - **Prescribed eye drops** (topical antibiotic and anti-inflammatory/corticosteroid, e.g., prednisolone acetate) are instilled as ordered (typically 4 times daily for 4 weeks, then tapered). - **Teach correct instillation technique:** Wash hands thoroughly, tilt the head back or lie supine, pull down the lower lid to form a pocket, look upward, instill the drop without touching the dropper to the eye, and gently close the eye. Punctal occlusion (apply gentle pressure to the inner corner of the eye for 1–2 minutes) is important to reduce systemic absorption. - **If more than one drop is ordered, wait 5 minutes between instillations** (to prevent washout of the first drop). - **Instill suspensions and ointments last** (they are thicker and may reduce absorption of other drops). **Expected Postoperative Timeline:** - **Day 1:** Mild discomfort, slight watering, blurred vision (common). - **Week 1:** Gradual improvement; sutures typically dissolve or are removed by day 7–10. - **Weeks 2–4:** Vision continues to stabilize; refraction stabilizes by 6 weeks (when glasses prescription can be finalized). - **Month 2–3:** Full visual recovery and stabilization. **Complications and Red-Flag Symptoms (Report Immediately)** - **Sudden severe eye pain** — may signal hemorrhage, acute glaucoma, or infection; requires urgent evaluation. - **Sudden vision loss or blurred vision** — suggests posterior capsular opacification, retinal detachment, or other serious complication. - **Increased redness or purulent discharge** — signs of infection. - **Flashes of light or new floaters** — may indicate retinal detachment. - **Halo effect or double vision** — common early but should not worsen; if severe, report. **Patient Education** - Reinforce that cataract surgery is **elective but highly successful** (>95% success rate in uncomplicated cases in the Philippines and worldwide). - Explain that **the lens cannot regrow**; if posterior capsule opacification develops (clouding of the bag holding the IOL), a simple laser procedure (YAG capsulotomy, takes minutes) opens it. - Advise regular follow-up eye exams (as recommended by the surgeon, typically at 1 week, 1 month, and 3 months post-op). - Clarify that **achieving plano (no refractive error) is ideal but uncommon**; most patients need glasses for reading or fine work post-op, or the IOL is set for monovision (one eye for distance, one for near). - In the Philippine context, emphasize the importance of attending follow-up appointments at the eye center or government hospital, as delayed detection of complications may lead to irreversible vision loss.

**Definition and Pathophysiology** Glaucoma is a group of disorders characterized by **increased intraocular pressure (IOP) that damages the optic nerve head**, resulting in progressive, **irreversible** loss of vision. Unlike the lens in cataract, optic nerve damage cannot be reversed; therefore, the goal is to detect glaucoma early and prevent further damage. Glaucoma is a leading cause of preventable blindness worldwide and in the Philippines. **Mechanism of IOP and Optic Nerve Damage** Normal IOP (10–21 mmHg) is maintained by a balance between aqueous humor production and drainage. When drainage is impaired (or rarely, production is excessive), IOP rises. Elevated IOP compresses the optic nerve head, reducing blood flow and causing ischemic damage to the nerve fibers. Initially, peripheral nerve fibers are affected (peripheral vision narrows—a process called "tunnel vision"), but if untreated, central vision eventually is lost. The damage is insidious because the patient often has no symptoms until significant damage has occurred. **Two Main Types: Open-Angle vs. Angle-Closure Glaucoma** **A. PRIMARY OPEN-ANGLE GLAUCOMA (POAG): The Chronic, Painless Form** **Pathophysiology:** The drainage angle (the space between the iris and cornea where aqueous humor exits) remains open, but aqueous outflow through the trabecular meshwork is gradually reduced, possibly due to: - Increased resistance in the trabecular meshwork (degeneration, fibrosis) - Reduced facility of outflow (normal facility decreases with age) - Elevated episcleral venous pressure Result: IOP rises slowly over months to years. **Clinical Presentation:** - **Asymptomatic in early stages** — called the "silent thief of sight" because patients often do not realize they have glaucoma until significant damage has occurred. - **Gradual, progressive loss of peripheral vision** (detected first on automated visual fields); central vision is preserved until late disease. - **Elevated IOP** (usually >21 mmHg, but some patients develop glaucoma at "normal" pressures—"normal-tension glaucoma"). - **Optic nerve head changes** on fundoscopy: increased cup-to-disc ratio, notching of the rim, laminar dot exposure. - **No pain, redness, or acute symptoms** — often discovered incidentally during routine eye exams. **Risk Factors:** - Age >60 years - Family history of glaucoma (genetic predisposition) - African or Hispanic descent (higher incidence and earlier onset) - Diabetes - Myopia (nearsightedness) - Prolonged corticosteroid use - Elevated baseline IOP **Diagnosis:** - **Tonometry:** Measurement of IOP (applanation or Goldmann tonometry is gold standard; rebound tonometry in the community setting). Single IOP reading does not diagnose glaucoma; serial measurements and IOP trends are important. - **Automated visual field testing (perimetry):** Shows characteristic glaucomatous defects—early arcuate scotomas (areas of vision loss following the nerve fiber layer pattern), nasal steps, or generalized depression. - **Fundoscopy/Optic Nerve Assessment:** Increased vertical cup-to-disc ratio (>0.6 is suspicious; >0.8 is highly suspicious), optic nerve rim thinning, splinter hemorrhages at the optic disc. - **Optical Coherence Tomography (OCT) of the optic nerve head:** Measures retinal nerve fiber layer (RNFL) thickness; thinning indicates damage. - **Gonioscopy:** Direct visualization of the drainage angle to confirm it is open (distinguishes open-angle from angle-closure). **Treatment: Lifelong IOP Reduction** The only proven treatment is **lowering IOP**. Each 1 mmHg reduction in IOP slows disease progression by about 10% (in some studies). Treatment is stepwise: **Step 1: Topical Medications (First-Line)** These are the initial treatment. The goal is to lower IOP by 25–30% from baseline. - **Prostaglandin Analogs (latanoprost, travoprost, bimatoprost):** - Mechanism: Increase uveoscleral (unconventional) aqueous outflow - Dosing: Once daily (often in the evening) - Side effects: Iris darkening and eyelash lengthening/darkening (reversible upon discontinuation); increased iris pigmentation; conjunctival hyperemia - **First-line in most countries** due to efficacy and once-daily dosing improving compliance - Contraindication: Herpetic keratitis (may worsen) - **Beta-Blockers (timolol, levobunolol, betaxolol):** - Mechanism: Decrease aqueous humor production by the ciliary body - Dosing: Twice daily (timolol) or once daily (some formulations) - Side effects: Systemic absorption can cause bradycardia, bronchospasm, fatigue, sexual dysfunction, hypotension - **Teaching on punctal occlusion:** Press gently on the inner corner of the eye (lacrimal canaliculus) for 1–2 minutes after instillation to occlude the drainage route and reduce systemic absorption—particularly important to prevent bradycardia and bronchospasm - **Contraindications:** Asthma, COPD, severe bradycardia, heart block, uncontrolled heart failure - Betaxolol (cardioselective) is safer in these patients but less effective - **Alpha-2 Agonists (brimonidine):** - Mechanism: Decrease aqueous production and increase uveoscleral outflow - Dosing: Three times daily - Side effects: Ocular allergy (frequent; can cause follicular conjunctivitis), systemic hypotension, dry mouth, drowsiness - **Caution:** Not recommended in children <2 years (risk of systemic absorption and CNS effects) - **Topical Carbonic Anhydrase Inhibitors (dorzolamide, brinzolamide):** - Mechanism: Decrease aqueous humor production by inhibiting carbonic anhydrase - Dosing: Dorzolamide three times daily; brinzolamide twice or three times daily - Side effects: Ocular stinging/irritation, bitter taste, local allergic reactions - Systemic effects rare with topical use (unlike systemic acetazolamide) - **Cholinergic/Miotic Agents (pilocarpine):** - Mechanism: Constrict the pupil (parasympathomimetic); useful in angle-closure by widening the angle - Dosing: Three to four times daily - Side effects: Ocular spasm and ache, myopia, reduced vision (especially in cataracts), systemic parasympathomimetic effects - **Less commonly used now** due to frequent dosing and side effects; primarily for acute angle-closure **Typical Medication Combinations:** If monotherapy does not achieve target IOP, combinations are used: - Prostaglandin analog + beta-blocker (synergistic; FDA combination available) - Prostaglandin analog + carbonic anhydrase inhibitor - Beta-blocker + carbonic anhydrase inhibitor - Some use triple therapy if needed **Step 2: Laser Treatment (If Medical Therapy Insufficient)** - **Argon Laser Trabeculoplasty (ALT)** or **Selective Laser Trabeculoplasty (SLT):** Uses laser to enhance aqueous drainage through the trabecular meshwork; can lower IOP by 20–30%. Effect may diminish over time (5–10 years); can be repeated. - **Laser Cyclophotocoagulation:** Destroys ciliary body tissue to reduce aqueous production; reserved for refractory cases or when surgery is not an option. **Step 3: Surgical Treatment (If Laser or Medical Therapy Fails)** - **Trabeculectomy:** Creates a fistula (new drainage pathway) between the anterior chamber and the subconjunctival space, bypassing the trabecular meshwork. Gold standard; lowers IOP significantly. Requires post-op care to prevent scarring. - **Glaucoma Drainage Implants (tubes):** For complex or refractory glaucoma; a small silicone tube drains aqueous to an external reservoir. - **Minimally Invasive Glaucoma Surgery (MIGS):** Newer techniques with smaller incisions and faster visual recovery (e.g., trabecular meshwork bypass, suprachoroidal shunt). **B. ACUTE ANGLE-CLOSURE GLAUCOMA: An Ophthalmic Emergency** **Pathophysiology:** The iris is pushed forward, suddenly blocking the drainage angle. Aqueous humor cannot drain; IOP rises acutely and dramatically (often to 40–80+ mmHg or higher). This is an **ocular emergency** because irreversible optic nerve damage can occur within hours. **Risk Factors:** - **Anatomically narrow drainage angles** (short axial length/hyperopia, thick lens, anterior lens position) - **Age 50–70 years** (lens thickens with age, crowding the angle) - **Female sex** (2–3 times more common than males, possibly due to smaller eye size) - **Family history** of angle-closure glaucoma - **Asian descent** (higher prevalence of anatomically narrow angles) - **Pupillary dilation** (from mydriatic medications—tropicamide, phenylephrine, atropine—or darkness, or stress) - **Medications with anticholinergic effects** (antihistamines, tricyclic antidepressants, atropine) can precipitate by dilating the pupil **Clinical Presentation: Acute and Dramatic** Unlike open-angle glaucoma, acute angle-closure presents with a **classic, unmistakable triad:** 1. **Severe eye pain** — often described as the worst eye pain the patient has experienced; may radiate to the temple, brow, or forehead 2. **Blurred vision with halos around lights** — rainbow-colored rings around point light sources (caused by corneal edema from high IOP) 3. **Red eye** — conjunctival and ciliary injection; the eye looks angry and inflamed **Additional Symptoms:** - **Fixed, mid-dilated pupil** (typically 4–6 mm, not reactive to light) — a hallmark sign - **Corneal haze** or opacity (from corneal edema) - **Nausea and vomiting** — from severe pain and increased IOP - **Headache** - **Photophobia** (light sensitivity) - **Rock-hard eye** on palpation (IOP very elevated) **Urgent Differential Diagnosis (Rule Out Mimics):** Acute angle-closure can mimic other acute eye and head problems: - Acute iritis/anterior uveitis (but pupils constrict, not dilate; less pain typically) - Acute conjunctivitis (no fixed pupil, no halos, minimal vision change) - Migraine headache (no fixed pupil, no halos, no red eye) - Acute corneal ulcer (pain, redness, but no halos; cornea has ulcer visible) **Diagnosis:** - **Tonometry:** IOP markedly elevated (>40 mmHg, often 60–80+ mmHg) - **Gonioscopy:** Direct visualization confirms angle is closed (iris touching trabecular meshwork) - **Anterior chamber depth assessment:** Slit-lamp or ultrasonic A-scan shows shallow anterior chamber - **Corneal clarity:** Haze from edema may obscure the view; clearing IOP allows better visualization **Urgent Treatment: The Golden Hours** Blindn**ess develops within 24–48 hours if untreated.** The goal is to break the attack, lower IOP rapidly, and then establish a permanent drainage route. **Immediate (Medical) IOP-Lowering:** 1. **Topical medications (immediate effect):** - **Beta-blockers (timolol 0.5%):** Instill every 15 minutes for 1–2 hours, then 4 times daily - **Alpha agonists (brimonidine):** Every 15 minutes initially - **Carbonic anhydrase inhibitors (dorzolamide or brinzolamide):** Every 15 minutes initially - **Avoid prostaglandin analogs and miotics initially** (may worsen angle-closure) - Later, once IOP is controlled, **pilocarpine (a miotic) may be added** to pull the iris away from the angle 2. **Systemic medications:** - **Acetazolamide (Diamox) 500 mg IV or PO** — rapidly reduces aqueous production; IV works faster (effect in 30 minutes); oral takes 1–2 hours. Common side effect: paresthesias (tingling in lips and fingers). - **Osmotic agents (IV mannitol or oral glycerol):** Draw fluid from the eye, shrinking the vitreous and deepening the anterior chamber. Mannitol 1 g/kg IV; effect in 30–45 minutes. Glycerol 50% PO if IV access unavailable. - **IV fluids:** To replace osmotic diuresis from mannitol/glycerol and prevent dehydration 3. **Analgesics:** Severe pain requires adequate analgesia (morphine or opioids IV/IM); pain control aids patient cooperation. 4. **Antiemetics:** For nausea/vomiting (ondansetron, metoclopramide). **Definitive (Surgical/Laser) Treatment:** Once IOP is controlled and cornea clears (usually 1–4 hours with aggressive medical therapy), a **laser peripheral iridotomy** is performed as an emergency. This creates a small opening in the iris, allowing aqueous to flow from the posterior chamber directly to the anterior chamber, bypassing the blocked pupil and permanently opening the angle. The procedure takes minutes and has a high success rate in breaking the acute attack and preventing recurrence. **Prophylactic Treatment of the Fellow Eye:** Because the contralateral eye also has narrow angles in most acute angle-closure cases, prophylactic laser iridotomy is performed on the fellow eye (even if asymptomatic) to prevent an acute attack there. **Complications of Acute Angle-Closure (If Untreated or Delayed):** - **Permanent blindness** (optic nerve atrophy from sustained high IOP) - **Ghost cells** (damaged RBCs in anterior chamber) - **Posterior synechiae** (adhesions between iris and lens) - **Permanent angle damage** (iris bows forward and sticks to angle structures permanently) **Nursing Care During Acute Attack:** - **Keep patient calm and still** (agitation and movement can worsen angle closure) - **Darkened room** (dilating pupil worsens angle closure; dim light helps) - **Position: Lie flat or recline** (some reports suggest supine position may slightly improve angle) - **IV access** for medications and fluids - **Monitor IOP closely** (serial tonometry); goal is reduction to <30 mmHg before laser - **Reassure patient** that this is treatable and vision can be saved - **Post-laser, discharge instructions:** Continue all prescribed drops; attend urgent follow-up in 1 week; report any recurrent pain or vision change; inform family members (genetic predisposition) to have angle assessment **Prevention and Screening for Angle-Closure:** Patients with anatomically narrow angles can be identified by: - **Gonioscopy:** Direct visualization (gold standard) - **A-scan biometry:** Measure axial length (short eye suggestive of narrow angles) - **Anterior chamber depth:** OCT or slit-lamp assessment - **Risk factors:** Family history, age, female sex, Asian descent Patients identified as having narrow angles should **avoid pupil-dilating medications** (some eye drops, antihistamines, certain antidepressants) and be counseled on the risk; prophylactic laser iridotomy may be offered to prevent acute attacks. **Patient Education on Glaucoma Management** 1. **Lifelong medication compliance:** Glaucoma drops must be taken daily and on schedule. Even one missed dose can allow IOP to rise; cumulative effect of non-compliance over weeks leads to progressive damage. 2. **Correct drop instillation:** Wash hands, tilt head back, pull down lower lid, instill without touching eye, apply punctal occlusion 1–2 minutes (especially important for beta-blockers to reduce systemic side effects). 3. **Possible side effects:** Warn of prostaglandin side effects (eyelash growth, iris darkening—cosmetic but permanent), beta-blocker side effects (fatigue, sexual dysfunction—systemic), and alpha-agonist side effects (local allergy). 4. **Regular eye exams:** IOP and visual fields must be monitored every 3–6 months to assess response to treatment; adjustments may be needed. 5. **Nutrition and exercise:** Moderate aerobic exercise (walking, swimming) may lower IOP slightly. Excessive caffeine should be limited (mild IOP-raising effect). No specific dietary interventions are proven, but overall eye health is promoted by antioxidants and UV protection. 6. **Sunglasses and UV protection:** Chronic UV exposure may contribute to glaucoma; recommend UV-protective sunglasses. 7. **Risk of acute angle-closure:** Educate on symptoms (severe eye pain, halos, blurred vision) and the need for immediate care if they develop. 8. **Informing family:** First-degree relatives (parents, siblings, children) have 5–10 times higher risk and should be screened. 9. **In the Philippine context:** Emphasize the importance of regular screening at the Philippine Academy of Ophthalmology (PAO)-accredited centers or government hospitals, as many Filipinos lack access to regular eye care; detect glaucoma early before irreversible damage occurs.

**Definition and Pathophysiology** Retinal detachment is separation of the **neurosensory retina** (the light-sensitive neural tissue) from the underlying **retinal pigment epithelium (RPE)**, which normally adheres to the retina and supplies it with oxygen and nutrients. Once separated, the retina becomes ischemic and begins to degenerate. Unlike cataracts or open-angle glaucoma, retinal detachment is an **acute emergency** requiring urgent surgical intervention to prevent permanent vision loss and blindness. **Types of Retinal Detachment:** 1. **Rhegmatogenous Detachment (Most Common, 90% of Cases)** - Caused by a break or tear in the retina (rhegma = tear/break) through which vitreous fluid seeps between the retina and RPE, pushing the retina away from the eye wall. - The retina is normally attached at the optic disc and the retinal blood vessels; elsewhere it floats loosely held by adhesion to the RPE. - When there is a retinal tear, the vitreous fluid (which fills the eye) flows through the tear into the potential space between retina and RPE, enlarging the detachment. - Risk factors: Myopia (nearsightedness—the long eye has more traction on the retina), previous eye surgery (cataract, glaucoma), trauma, lattice degeneration, strong family history (10–15% in relatives of affected patients), and advanced age. 2. **Tractional Detachment** - Scar tissue (from diabetes, previous inflammation, or trauma) physically pulls the retina away from the RPE. - Common in advanced diabetic retinopathy. 3. **Exudative Detachment** - Fluid accumulates beneath the retina (from inflammation, tumor, or other cause) without a retinal break. - The retina is not torn; fluid under it causes detachment. **Clinical Presentation: The Classic Triad (CRITICAL for NLE)** Retinal detachment presents acutely with a classic set of symptoms: 1. **Sudden Floaters** — New appearance of spots, "cobwebs," or dark shapes floating in the visual field. These are actually vitreous opacities or blood from the torn vessel at the tear. The patient may say "I see a lot of black dots or lines moving around." 2. **Flashes of Light (Photopsia)** — Sudden, brief, bright flashes perceived in the peripheral field (from mechanical stimulation of the retina by the separating vitreous gel). 3. **Curtain or Shadow Spreading Across the Visual Field** — A dark shadow, veil, or curtain that progressively encroaches on vision, usually from the periphery moving inward. This represents the advancing edge of detached retina; the patient might describe it as "a dark curtain coming down from above" or "coming in from the side." **Important: The Detachment is Usually PAINLESS** (unlike glaucoma or uveitis) because the retina has no pain receptors. **Progression:** - If the macula (the central, most vision-critical region of the retina) is not involved at presentation, the patient may have relatively preserved central vision with peripheral vision loss. - As the detachment progresses and/or if it reaches the macula, central vision becomes significantly blurred, and if the detachment goes untreated, complete blindness of that eye results. **Physical Examination Findings:** - **Reduced or absent red reflex** (the normally bright red glow of the retina seen on ophthalmoscopy; a detached retina appears dark/black) - **Visual field defect** (on confrontation testing, the field defect corresponds to the detached area) - **Retinal break or tear may be visible** on careful fundoscopy, though visualization may be difficult if there is vitreous hemorrhage - **Vitreous hemorrhage** (blood in the vitreous obscuring the view) - **Absence of pain and normal pupil reactivity** **Differential Diagnosis:** Similar symptoms can occur with: - **Posterior vitreous detachment (PVD)** — the vitreous gel naturally separates from the retina with aging; causes floaters and flashes but not detachment if the retina remains attached. However, PVD can lead to retinal breaks and detachment. - **Vitreous hemorrhage without detachment** — bleeding into the vitreous from various causes (diabetes, retinal vein occlusion, branch retinal artery occlusion) causes floaters and vision loss but not a "curtain" shadow; ultrasound helps differentiate. - **Amaurosis fugax** (transient monocular blindness) — sudden complete vision loss in one eye from carotid artery disease or emboli; lasts seconds to minutes and resolves; no floaters/flashes. **Diagnosis:** - **Clinical presentation** — the history of floaters, flashes, and shadow/curtain is highly suggestive. - **Ophthalmoscopy (indirect or direct):** Gold standard; visualizes retinal breaks or the edge of the detached retina (which appears elevated, corrugated, and darker than attached retina). - **B-scan ultrasound:** If vitreous hemorrhage prevents clear visualization; shows characteristic pattern of detached retina. - **OCT:** May show detachment if media is clear enough. **Treatment: URGENT SURGICAL REATTACHMENT** Retinal detachment **cannot resolve on its own** and will lead to blindness if not repaired surgically. The goal of surgery is to: 1. Close the retinal break 2. Reattach the retina to the RPE 3. Restore blood and oxygen supply to the retina **Timing:** - **Macula-on detachment (macula not yet detached):** Ideally repaired within 24–48 hours; urgency is lower than macula-off but still within days. - **Macula-off detachment (macula already detached):** Ideally repaired within 24 hours, though studies show visual outcomes continue to improve even when surgery is delayed slightly; waiting weeks or months results in severe permanent vision loss. **Surgical Techniques:** 1. **Scleral Buckling (SB):** Most traditional approach - A silicone band or sponge (explant) is sutured to the sclera (white of the eye) on the outside, over the site of the retinal break. - The sclera is indented inward toward the vitreous, reducing traction on the retina and allowing the retinal break to close. - The vitreous is often drained through a small incision to allow the retina to reattach. - An air bubble or silicone oil bubble may be injected into the vitreous to tamponade (push) the retina against the RPE while it reattaches. - Success rate: ~80–90% with single SB; may require repeat if redetachment occurs. - Advantages: Preserves the eye's natural anatomy; good for peripheral breaks. - Disadvantages: Retrobulbar (behind-the-eye) surgery; longer healing; may cause myopic shift (the eye becomes more nearsighted because of buckle); eyelid symptoms; required post-op positioning may be prolonged. 2. **Pneumatic Retinopexy (PR):** For selected cases - An expandable gas bubble (air, sulfur hexafluoride [SF6], or perfluoropropane [C3F8]) is injected directly into the vitreous. - The gas bubble rises and pushes the detached retina back against the eye wall, tamponading it while it reattaches. - Requires that the retinal break be in the superior (upper) half of the eye so the bubble can effectively push it. - Post-operative head positioning is critical: the patient must position their head so the gas bubble rests against the retinal break for days to weeks. - Success rate: ~75–85% for selected cases. - Advantages: Avoids external surgery; faster visual recovery. - Disadvantages: Strict head positioning required; limited to specific break locations; cannot fly or travel to high altitude until gas is absorbed (risk of expansion); redetachment risk if positioning not maintained. 3. **Vitrectomy with Internal Tamponade:** For complex cases - The vitreous gel is removed (vitrectomy) via small incisions (usually 23-gauge, 25-gauge, or 27-gauge needles). - The retinal break is identified and closed (with laser or cryotherapy—cold probe). - Internal tamponade is achieved with a gas bubble or silicone oil. - Advantages: Direct visualization of the break; can treat multiple breaks; good for vitreous hemorrhage or proliferative vitreoretinopathy (PVR). - Disadvantages: Faster cataract formation post-op; more technically demanding; may require longer post-op positioning than SB. **Selection of Technique:** Depends on: - Location of the retinal break (SB good for peripheral; vitrectomy for posterior) - Clarity of the media (vitreous hemorrhage → vitrectomy) - Complexity (single break → SB or PR; multiple breaks, PVR → vitrectomy) - Surgeon expertise and patient factors **Preoperative Nursing Care:** - **Ensure informed consent:** Explain the procedure, expected outcomes (reattachment may be successful but vision may not fully return if macula was off for a long time), and the importance of post-op positioning (if applicable). - **Keep NPO** (nothing by mouth) for 6–8 hours if general anesthesia planned (many retinal surgeries use regional or local anesthesia, so NPO may be less strict). - **Dilate pupils** with mydriatic drops to allow surgical visualization. - **Instill antibiotic drops** (prophylaxis) before surgery. - **Baseline visual acuity** and eye exam documentation. - **Emotional support:** Patients are often anxious about potential blindness; reassure that urgent surgery offers good chance of preserving vision. **Postoperative Nursing Care: The CRITICAL Role of Head Positioning** The most important nursing intervention post-op is ensuring **correct head positioning** as prescribed by the surgeon. This cannot be overemphasized. **If Gas Bubble Tamponade (Pneumatic Retinopexy or Vitrectomy with Gas):** - The patient must **position their head so the gas bubble is in direct contact with the retinal break**, tamponading (pressing) it while the retina reattaches. - **Typical positioning:** - "Face-down" — chin on the chest, eyes toward floor (for breaks in the inferior/lower part of the retina) - "Eyes up" — eyes toward ceiling (for breaks in the superior/upper part) - "Strict head positioning" — the patient must maintain this position 24/7 (except brief breaks for essential activities) for days to weeks (typically 10–14 days). - **Compliance is crucial.** If the patient moves away from the required position, the gas bubble drifts and the retina may redetach. - **Duration:** Depends on bubble type and surgeon preference; SF6 bubble lasts ~1–2 weeks, C3F8 lasts ~6–8 weeks; gas gradually is absorbed and replaced by the eye's natural fluids. - **Activity restrictions during gas phase:** - **Absolutely NO air travel** — airplane cabin pressurization at altitude causes gas to expand, raising IOP dramatically and damaging the eye (an ophthalmic emergency). Must not fly until gas is completely absorbed (confirmed by the surgeon at follow-up). If the patient has already traveled by air, they must be seen urgently to rule out super-acute elevated IOP. - **No high altitudes** (hiking in mountains or any elevation >1,000 feet for SF6; <5,000 feet for C3F8) — same reason as air travel. - **Avoid driving** — head position makes this unsafe. - **Patient comfort:** Prolonged face-down positioning is challenging and causes discomfort (neck pain, low back pain, facial swelling). Provide: - **Positioning pillows or special head rests** designed for prone positioning - **Anti-nausea medications** if needed (positioning can trigger dizziness/nausea) - **Analgesics** for neck and back pain - **Frequent position changes** within the allowed head position range (slightly left, slightly right) to reduce pressure areas - **Encouragement and reassurance** **If Silicone Oil Tamponade (For Complex Cases):** - Silicone oil is heavier than gas and sinks (gravity-dependent); positioning is less strict but may be recommended. - Silicone oil may be left in place for months to years or may be removed after reattachment. - Limitations of silicone oil: Cataracts form rapidly; IOP may rise; vision is somewhat reduced (oil in light path); requires removal procedure later. **If Scleral Buckle Alone (No Internal Tamponade):** - Less strict positioning; the buckle itself holds the retina in place. - Some patients may be asked to avoid strenuous activity or heavy lifting for a few weeks. - Recovery is generally slower than with modern vitrectomy techniques. **Other Postoperative Care:** - **Eye protection:** Eye shield or protective glasses; avoid getting water in the eye. - **Activity:** Bed rest or limited activity per surgeon instructions; no heavy lifting, strenuous exercise, or Valsalva for weeks. - **Medications:** Antibiotic and anti-inflammatory drops as prescribed; analgesics for pain. - **Sutures:** If present, removed at 1–2 weeks follow-up (or may be absorbable). - **Follow-up exams:** At 1 day, 1 week, 1 month post-op to assess reattachment, IOP, and cataract formation (common post-op). **Reattachment and Visual Outcomes:** - **Anatomic success:** Retina is reattached (80–95% depending on complexity and technique). - **Visual outcome:** Depends on: - Whether the macula was detached (macula-on detections often have excellent visual recovery; macula-off has variable recovery depending on duration of detachment) - Time from detachment to surgery (longer delay → worse outcome) - Extent of detachment - Pre-operative vision - Many patients recover good central vision; some retain a permanent visual field defect corresponding to the detached area. - **Redetachment:** Can occur in 5–20% of cases within weeks to years; re-surgery is usually successful. **Patient Education:** 1. **Recognize symptoms of retinal detachment:** Sudden floaters (especially if new and increasing), flashes of light, or a shadow/curtain moving across vision is an **ophthalmic emergency.** 2. **Immediate action:** Contact an eye doctor or go to the emergency room immediately. Do not drive if vision is compromised; arrange transport. 3. **Post-op positioning:** Emphasize the critical importance of maintaining head position as prescribed; the difference between strict compliance and non-compliance is sight vs. blindness. 4. **Air travel and altitude:** Do not fly and do not travel to high altitudes until cleared by the surgeon; the eye can be damaged irreversibly. 5. **Prevent future detachment:** Wear eye protection during sports/activities to prevent trauma; myopic patients should be aware of their increased risk and educated on recognizing early symptoms. 6. **In the Philippine context:** Many patients may not have easy access to urgent retinal surgery; emphasize the need to go to a referral center (government hospital with ophthalmology/retina services or accredited private eye hospital) immediately if symptoms occur. Delaying surgery by even a few days can result in permanent vision loss. Advocate for awareness in the community. 7. **Family screening:** Relatives should be counseled on symptoms, as familial clustering occurs (especially in high myopia). **Red-Flag Complications:** - **Proliferative vitreoretinopathy (PVR):** Scar tissue forms on the retinal surface, contracting and pulling the retina away again; complicates surgery; higher risk if surgery is delayed. - **Silicone oil-related glaucoma:** IOP rises; may require oil removal or glaucoma surgery. - **Cataract formation:** Very common post-op, especially with gas or silicone oil; may require cataract surgery. - **Redetachment:** If the retina reattaches but slips again, re-operation is needed.

**Definition** Otitis media is inflammation and/or infection of the middle ear, the air-filled space behind the tympanic membrane containing the ossicles. It is one of the most common infections in children, though it can occur at any age. **Anatomy and Eustachian Tube Dysfunction** The eustachian tube connects the middle ear to the nasopharynx and serves three functions: 1. Equalize air pressure in the middle ear with atmospheric pressure 2. Drain secretions from the middle ear into the nasopharynx 3. Protect the middle ear from nasopharyngeal secretions and pathogens In children, the eustachian tube is **shorter (approximately horizontal) and wider than in adults**; additionally, its muscular support is not fully developed. This anatomic difference makes children more prone to: - Reflux of nasopharyngeal secretions into the middle ear - Retained fluid and infection - Recurrent episodes (on average, children have 3 episodes of acute otitis media by age 3 years) **Types of Otitis Media** 1. **Acute Otitis Media (AOM):** Acute infection of the middle ear with rapid onset of symptoms. 2. **Otitis Media with Effusion (OME) or "Serous Otitis":** Persistent fluid in the middle ear without acute infection; may follow AOM or occur independently. 3. **Chronic Otitis Media:** Recurrent or persistent infection with possible perforation of the tympanum and drainage. **Etiology (AOM)** Most commonly bacterial: - **Streptococcus pneumoniae** (pneumococcus) — historically most common; incidence decreased since pneumococcal vaccination - **Haemophilus influenzae type b** (and non-typeable strains) — common - **Moraxella catarrhalis** — common - **Viral:** Often follows upper respiratory infection (URI); viral infection causes inflammation and eustachian tube dysfunction, allowing bacterial overgrowth **Risk Factors** - **Age 6 months to 3 years** — peak incidence - **Recent upper respiratory infection** or nasopharyngeal colonization - **Negative pressure in the middle ear** from eustachian tube obstruction (adenoid hypertrophy, allergies, environmental smoke) - **Attending day care** (increased pathogen exposure) - **Pacifier use** (may impair eustachian tube function) - **Bottle feeding while lying down** (formula can reflux into eustachian tube) - **Smoking exposure** (damages mucociliary clearance) - **Cleft palate** (abnormal tensor tympani muscle) - **Immunodeficiency** **Pathophysiology** 1. Eustachian tube dysfunction → negative pressure in middle ear → fluid accumulation 2. Bacterial colonization of this fluid → purulent middle ear fluid 3. Accumulation of pus → tympanic membrane becomes tense and bulges 4. If pressure is high enough, the tympanum may rupture, draining pus into the external canal 5. If untreated, infection can spread to adjacent structures (mastoiditis, meningitis) **Clinical Presentation** **In Young Children (who may not verbalize symptoms):** - **Ear pain or "pulling at the ear"** (classic sign; child may tug at affected ear) - **Fever** (often 38–40°C) - **Irritability, crying, restlessness** (especially lying down, as pressure increases in middle ear) - **Reduced hearing** or lack of response to sounds - **Diarrhea, vomiting, anorexia** (non-specific GI symptoms common in children with fever) - **Drainage from the ear** (if tympanum ruptured) - **Sleep disturbance** (pain worse when lying flat) **In Older Children and Adults:** - **Ear pain (otalgia)** — may be severe - **Feeling of fullness** in the ear - **Conductive hearing loss** (temporary) - **Tinnitus** (ringing in the ear) **Physical Examination Findings** - **Otoscopic examination:** The gold standard for diagnosis - **Tympanic membrane:** Bulging, red (inflamed), dull (from fluid behind it), loss of normal landmarks (the cone of light reflex is diminished or absent) - **Air-fluid level or bubble:** May be visible through the membrane if fluid is present - **Perforation:** If tympanum has ruptured, a hole is visible with purulent drainage - **Auricle:** May be tender to touch (but less so than in otitis externa) - **Hearing:** Conductive hearing loss on Weber or Rinne testing - **Fever:** Usually present **Diagnosis** - **Clinical diagnosis** based on symptoms + otoscopic findings (bulging, red, dull tympanum) - **Tympanometry:** Confirmatory; shows normal middle ear pressure in healthy ears; low compliance indicates middle ear effusion - **Audiometry:** May show conductive hearing loss - **Culture of middle ear fluid:** Not routine; reserved for cases with complications or recurrent AOM **Treatment** **Watchful Waiting vs. Antibiotics** Historically, all cases of AOM were treated with antibiotics. Current practice varies by guideline and clinical context: - **American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP):** "Watchful waiting" is acceptable for children >6 months with mild symptoms (not severe pain, fever <39°C, symptom onset <48 hours), as many cases resolve spontaneously. - **Delayed antibiotics:** If "wait-and-see" is chosen, antibiotics are provided with instructions to start if symptoms worsen or do not improve in 48–72 hours. - **Antibiotics immediately** if: - Age <6 months - Severe symptoms (severe otalgia, fever ≥39°C) - Symptoms >48 hours - Immunocompromised - Uncertain follow-up - Bilateral AOM - Concurrent mastoiditis or meningitis **Antibiotic Therapy** **First-line (in the Philippines and most countries):** - **Amoxicillin:** 40–45 mg/kg/day in 3 divided doses for 10 days (still commonly used despite increasing resistance) - **Amoxicillin-clavulanate (Augmentin):** Covers beta-lactamase-producing organisms; especially if resistant pneumococcus or H. influenzae suspected - **Higher-dose amoxicillin** (80–90 mg/kg/day) is used in some countries for better coverage of resistant S. pneumoniae **Alternatives (if penicillin allergy, resistance, or intolerance):** - **Cephalosporin** (cefixime, cefpodoxime, cephalexin) — if penicillin allergy is non-severe - **Macrolide** (azithromycin, erythromycin) — if true penicillin allergy - **Fluoroquinolone** (levofloxacin, moxifloxacin) — reserved for resistant organisms or systemic infection (meningitis) **Course of Antibiotics:** - **Duration:** 10 days is standard for AOM (to eradicate bacteria and prevent complications) - **Response:** Most children improve within 48–72 hours (fever resolves, pain improves) - **Compliance:** Parents must be counseled to complete the full course even if the child feels better (incomplete treatment leads to recurrence and resistance) **Symptomatic Care** - **Analgesics:** Ibuprofen or acetaminophen for pain and fever (reduce otalgia and improve sleep) - **Decongestants:** Phenylephrine nasal drops or pseudoephedrine systemic (controversial; may help some children by reducing eustachian tube congestion, but not routinely recommended) - **Topical decongestants or antihistamines:** Limited evidence; not routinely used - **Keep ear dry:** No water in the ear until healed (if perforation present, water can introduce bacteria) - **Warm compress to the ear:** For comfort **Complications** **Common:** - **Tympanic membrane perforation:** Pus ruptures the membrane; typically self-seals within 2 weeks - **Otitis media with effusion (OME):** Fluid persists after acute infection resolves; causes conductive hearing loss **Uncommon but Serious (if untreated or complicated):** - **Mastoiditis:** Infection spreads to the mastoid bone; presents with post-auricular swelling, fever, headache; requires IV antibiotics and possible mastoid drainage or tympanostomy - **Meningitis:** Infection spreads to the meninges; presents with nuchal rigidity, high fever, altered mental status, headache; medical emergency - **Facial nerve palsy:** Rare; from inflammation or infection of CN VII in its middle ear course - **Labyrinthitis:** Infection spreads to the inner ear; presents with vertigo, nausea, vomiting, hearing loss **Recurrent Otitis Media** Defined as **three or more episodes in 6 months, or four or more in 12 months.** In the Philippines and many countries, this is common due to high prevalence of URIs, day care exposure, and sometimes suboptimal follow-up care. **Management of Recurrent AOM:** - **Identify and modify risk factors:** Eliminate smoking exposure, optimize bottle-feeding position (upright, not flat), consider day care alternatives if possible, treat allergies if present - **Prophylactic antibiotics:** Low-dose amoxicillin (e.g., 20 mg/kg/day) or sulfisoxazole given daily throughout the winter/cold season; controversial and not universally recommended (risk of resistance) - **Tympanostomy (ventilation) tubes:** **Myringotomy with tube insertion** is the definitive surgical treatment. Indications include: - Recurrent AOM (≥3 in 6 months) with documented middle ear effusion - OME with hearing loss persisting >3 months - Failed medical management - The tubes remain in place for 6–12 months, then extrude (self-expel) as healing occurs; many children do not have recurrence after tubes are removed - Success rate in reducing recurrent infections: 70–85% **Tympanostomy Tube Precautions (Critical for Nursing):** - **No water in the ears:** Water entering through the tubes can cause drainage and infection. Patients should: - Wear custom earpieces or cotton with Vaseline during bathing/showering - Avoid swimming or water sports (unless using custom swimming ear plugs) - Dry ears gently if water enters - **If drainage occurs:** Clean gently with cotton-tipped swab; use topical antibiotic-corticosteroid otic drops (e.g., ciprofloxacin-dexamethasone); report persistent drainage - **Regular follow-up:** Tubes are checked at routine pediatric visits to ensure they are patent and in place - **No air travel pressure changes:** Tubes equalize pressure, so air travel is generally safe, but rapid pressure changes may cause discomfort; encourage nasal decongestants 30 minutes before flight **Patient/Parent Education for Otitis Media** 1. **Complete antibiotics:** Even if the child feels better after a few days, complete the full 10-day course; incomplete treatment leads to recurrence and antibiotic resistance. 2. **Recognize symptoms:** Ear pain, fever, pulling at ear, drainage, or reduced hearing in a child with URI warrants evaluation. 3. **Risk factors:** Explain how eustachian tube dysfunction in children leads to infection; discuss modifiable risk factors (smoking exposure, bottle-feeding position, day care). 4. **Complications:** Warn of serious but preventable complications (mastoiditis, meningitis) if symptoms worsen or persist; seek urgent care if child develops high fever, severe pain, lethargy, or neck stiffness. 5. **Tubes (if placed):** Teach water precautions and importance of keeping ears dry; explain that tubes usually extrude on their own; routine follow-up with ENT is essential. 6. **Follow-up:** Hearing assessment is recommended if recurrent AOM occurs, especially if OME persists; early intervention is important for speech and language development in young children. 7. **In the Philippine context:** Many families may not have easy access to audiometry or specialized ENT care. Emphasize the importance of early recognition and treatment to prevent hearing loss (which can affect school performance and social development). Community health workers and barangay health centers can help identify children with hearing loss early.

**Definition and Pathophysiology** Ménière's disease (also called Ménière syndrome) is a chronic inner-ear disorder caused by **abnormal accumulation of endolymph** (the fluid inside the membranous labyrinth of the inner ear), also called **endolymphatic hydrops**. The accumulation of fluid causes increased pressure in the semicircular canals (vestibular apparatus) and cochlea, resulting in a characteristic triad of symptoms. **Anatomy Review (Relevant to Ménière's)** - The inner ear contains two fluid systems: - **Endolymph:** Fluid inside the membranous labyrinth (cochlear duct, vestibular apparatus) - **Perilymph:** Fluid surrounding the membranous labyrinth in the bony labyrinth - **Cochlea:** Converts sound vibrations to neural signals; has hair cells sensitive to different frequencies - **Vestibular apparatus:** Semicircular canals (detect head rotation) and utricle/saccule (detect linear acceleration and head position); hair cells in these structures send balance signals via CN VIII - **Endolymphatic sac:** Drains endolymph; dysfunction or obstruction can cause hydrops **Etiology and Risk Factors** The exact cause of Ménière's disease is unknown, but theories include: - **Endolymphatic sac dysfunction:** Impaired drainage of endolymph, causing accumulation - **Genetic predisposition:** Some familial clusters reported - **Viral infection:** May trigger inflammation and drainage impairment - **Allergy:** Proposed but controversial - **Autoimmune mechanism:** Some evidence for immune-mediated inflammation of the labyrinth - **Migraine:** Association observed (migraine in 25–50% of Ménière's patients) - **Trauma:** Prior head injury may predispose ("post-traumatic Ménière's") - **Stress:** Psychological stress may exacerbate symptoms - **Sodium intake and fluid imbalance:** Proposed but not definitively proven **Incidence and Demographics** - **Peak age:** 40–60 years (can occur younger or older) - **Prevalence:** 3.5 per 100,000 people - **Unilateral vs. bilateral:** 60–70% remain unilateral; 15–30% become bilateral over 5–10 years - **No gender predilection** in most studies (previously thought to be more common in women) **Clinical Presentation: The Classic Triad** Ménière's disease presents with a characteristic triad (often called the "Ménière's triad"): **1. EPISODIC VERTIGO (The Hallmark)** - **Severe, spinning sensation (true vertigo)** — not lightheadedness or dizziness, but a feeling that the room is spinning around the patient or the patient is spinning - **Sudden onset:** Attacks begin abruptly without warning (some patients report mild dizziness or aural fullness in the hours before a full attack) - **Severe intensity:** Often disabling; patient cannot stand or walk safely - **Nystagmus:** Involuntary eye movements in one direction (typically horizontal-rotatory), accentuating the sensation of spinning - **Nausea and vomiting:** Severe, often accompanying the vertigo; may occur during or after the attack - **Duration:** Episodes last **20 minutes to several hours** (typically 1–3 hours); full recovery can take days - **Frequency:** Highly variable; some patients have attacks weekly, others have them months apart. Attacks are **unpredictable**, making the condition psychologically stressful - **Complete recovery between attacks:** Between episodes, the patient has no vertigo (unlike central causes where dizziness may be constant) - **During attacks:** Patient is incapacitated; bed rest in a dark, quiet room is typical management **2. TINNITUS (Ringing in the Ear)** - **Subjective sensation of sound** in the affected ear(s) — typically a low-frequency roaring or rushing sound (like ocean waves, machinery, or a jet engine); may also be described as a buzzing or humming - **May be constant or episodic** — some patients have tinnitus all the time, others only during attacks - **Often worsens during or preceding an attack** - **May increase in severity over time** in some patients (progressive tinnitus) - **Distressing:** Can interfere with sleep and concentration **3. FLUCTUATING SENSORINEURAL HEARING LOSS** - **Sensorineural (not conductive):** The loss is from inner ear damage (cochlear hair cells or CN VIII), not middle ear obstruction - **Fluctuating:** Hearing varies day to day or week to week; may improve after an attack or gradually worsen over time - **Low-frequency loss:** Early in disease, hearing loss is in the low frequencies (bass sounds); with progression, mid and high frequencies are affected - **Can progress to permanent hearing loss:** If the disease progresses, fluctuating loss becomes permanent fixed loss - **Audiometry shows sensorineural pattern:** Weber test—tone lateralizes to the unaffected (better-hearing) ear; Rinne test shows bone conduction > air conduction on the affected side **Associated Symptoms:** - **Aural fullness or pressure:** Feeling of fullness in the affected ear (from endolymphatic hydrops) - **Auditory recruitment:** In some patients, loud sounds are perceived as abnormally loud or uncomfortable (due to cochlear pathology) - **Oscillopsia:** Blurring of vision during or immediately after an attack (from nystagmus) **Atypical Presentations:** - **Cochlear Ménière's:** Hearing loss and tinnitus without vertigo - **Vestibular Ménière's:** Vertigo without hearing loss or tinnitus - **Ménière's "drops" (Tumarkin otolithic crisis):** Sudden falls without warning or vertigo (rare, frightening) **Diagnosis** Diagnosis is primarily **clinical**, based on characteristic history. There is no single definitive test. **Diagnostic Criteria (Modified AAO-HNS Criteria):** - **Definite Ménière's:** Two or more spontaneous episodes of vertigo lasting 20 minutes to 12 hours, AND audiometrically documented hearing loss on at least one occasion, AND tinnitus or aural fullness, AND other causes ruled out - **Probable Ménière's:** One spontaneous vertigo episode, AND audiometrically documented hearing loss, AND tinnitus or aural fullness, AND other causes ruled out **Differential Diagnosis (Rule Out):** - **Vestibular neuritis:** Vertigo without hearing loss; usually preceded by viral illness - **Benign paroxysmal positional vertigo (BPPV):** Brief episodes (seconds to minutes, not hours) triggered by position changes; Dix-Hallpike test positive - **Vestibular migraine:** Associated migraine headache; vertigo can precede or accompany migraine - **Acoustic neuroma:** Progressive sensorineural hearing loss and tinnitus but vertigo is uncommon; MRI shows tumor - **Labyrinthitis:** Viral or bacterial infection causing acute vertigo, hearing loss, tinnitus; often follows URI; not episodic - **Superior semicircular canal dehiscence:** Rare; presents with vertigo provoked by specific sounds or pressure changes; CT/HRCT imaging shows bone defect **Investigations (If Diagnosis Uncertain or to Support Clinical Diagnosis):** - **Audiometry:** Demonstrates low-frequency sensorineural hearing loss; serial audiograms document fluctuation - **Electronystagmography (ENG) or Videonystagmography (VNG):** Detects nystagmus during attacks; normal between attacks - **Caloric testing:** Assesses vestibular function; may show hypoactive response on affected side during active disease - **Calorics/Dix-Hallpike:** Negative in Ménière's (positive in BPPV) - **MRI of the internal auditory canal and brain:** To exclude acoustic neuroma or central causes (typically normal in Ménière's but performed to rule out mimics) - **Gadolinium-enhanced MRI of the labyrinth:** Experimental; may show endolymphatic hydrops (not routinely done) - **Electrocochleography (ECoG):** Detects cochlear electrolyte abnormalities from hydrops; may be abnormal in Ménière's but not specific **Treatment: Stepwise Approach** There is no cure for Ménière's disease, but symptoms can be managed. Treatment aims to control vertigo and stabilize hearing. Management is **stepwise**, progressing from conservative to more aggressive interventions. **STEP 1: Lifestyle and Dietary Modifications (First-Line, Always Recommended)** **Sodium Restriction:** - **Low-sodium diet:** Limit sodium to <2000 mg/day (or <1500 mg/day in some recommendations); rationale is that reduced dietary sodium may decrease endolymphatic fluid volume - **Avoid salt-cured, processed, and fast foods** - **Patient compliance is challenging** but important; patient counseling and dietitian referral helpful - **Evidence:** Sodium restriction combined with diuretics shows benefit in some studies; benefit is modest **Diuretics:** - **Furosemide (Lasix) or thiazide diuretics:** May reduce endolymphatic volume, theoretically lessening pressure and symptom frequency - **Typical dose:** Furosemide 40 mg daily or twice daily; hydrochlorothiazide 25–50 mg daily - **Monitoring:** Check electrolytes (especially potassium, which can drop with diuretics) and renal function regularly - **Evidence:** Modest benefit in controlling vertigo attacks in some studies; often combined with low-sodium diet **Fluid Intake:** - **Adequate hydration:** Ensure patient is well-hydrated (dehydration can exacerbate symptoms) - **Limit caffeine, alcohol, and nicotine:** These substances may alter inner ear fluid balance; their restriction is often recommended - **Some patients report symptom improvement** with these restrictions, but evidence is limited **Stress Management:** - **Stress reduction:** Practice relaxation techniques, yoga, meditation; psychological stress may trigger or worsen attacks - **Sleep:** Ensure adequate sleep; sleep deprivation may increase attack frequency **STEP 2: Pharmacologic Management (For Acute Attacks and Preventive)** **For Acute Vertigo Attack:** - **Antihistamines/vestibular suppressants:** - **Meclizine (Antivert, Dramamine):** 25–50 mg every 4–6 hours; reduces vertigo sensation by suppressing vestibular center input to the vomiting center - **Diphenhydramine:** 25–50 mg IV/IM or PO; useful in acute setting - **Promethazine:** 12.5–25 mg IV/IM or PO - **Onset:** Oral forms take 1–2 hours; IV/IM faster (useful if severe nausea/vomiting prevents oral intake) - **Antiemetics:** - **Ondansetron (Zofran):** 4–8 mg IV or 8 mg PO three times daily; very effective for nausea/vomiting; does not treat vertigo directly but improves comfort - **Promethazine:** Acts as both vestibular suppressant and antiemetic - **Metoclopramide:** 10 mg IV/IM or PO; useful if gastric stasis occurs - **Anticholinergics:** - **Scopolamine (hyoscine):** Transdermal patch (0.5 mg); applied behind ear for extended relief; useful for nausea/vomiting; side effects include dry mouth and blurred vision - **Atropine:** IV in acute setting; useful if severe symptoms - **Anxiolytics (Judiciously):** - **Diazepam:** 2–5 mg IV/IM during acute attack; reduces anxiety and provides vestibular suppression - **Caution:** Benzodiazepines carry risk of dependence and fall risk, especially in elderly; used only during acute attacks and for short duration **For Prevention of Attacks:** - **Tricyclic antidepressants:** - **Amitriptyline:** 10–75 mg at bedtime; reduces attack frequency and severity; mechanism unclear (possibly mood stabilization or vestibular dampening) - **Nortriptyline:** Alternative tricyclic; less sedating - **Side effects:** Sedation, dry mouth, weight gain, sexual dysfunction; therapeutic lag of 1–2 weeks - **Beta-blockers:** - **Propranolol:** 40–120 mg daily in divided doses; some evidence for reducing attack frequency - **Mechanism:** Unknown; possibly vestibular dampening - **Calcium channel blockers:** - **Flunarizine:** 10 mg daily; used in some countries (less common in the US); may reduce attack frequency - **Corticosteroids:** - **Intratympanic dexamethasone or methylprednisolone:** Injected into the middle ear (via myringotomy) to reach the inner ear directly; may reduce attack frequency and hearing loss progression - **Typical protocol:** Series of 3–4 injections over several weeks - **Evidence:** Some benefit in controlling vertigo; unclear benefit for hearing preservation - **Systemic corticosteroids (oral prednisone):** Used in some cases of acute attack or early active disease; typically high-dose taper over weeks - **Combinations:** Patients often require combinations (low-sodium diet + diuretic + amitriptyline + vestibular suppressant as needed) for optimal control **STEP 3: Procedural/Surgical Interventions (If Medical Management Fails)** Used when conservative measures do not adequately control symptoms, particularly vertigo. - **Intratympanic gentamicin (Ototoxic aminoglycoside):** - **Goal:** Ablate (destroy) vestibular function selectively while preserving hearing - **Procedure:** Gentamicin solution injected into middle ear via myringotomy; diffuses into inner ear - **Typical protocol:** Weekly or less frequent injections until vertigo controlled - **Efficacy:** 80–90% control of vertigo - **Risk:** Hearing loss (5–30% risk), particularly if multiple high-dose injections used; careful monitoring essential - **Advantage:** Less invasive than labyrinthectomy; can be repeated or converted to labyrinthectomy if fails - **Endolymphatic sac decompression/shunting:** - **Goal:** Enhance drainage of endolymph to reduce pressure - **Procedure:** Surgical decompression or insertion of a shunt from endolymphatic sac to subarachnoid space or mastoid space - **Efficacy:** Variable (60–80% in early reports; reproducibility questioned); some studies show placebo effect is significant - **Advantage:** Hearing and vestibular function often preserved - **Currently:** Less popular than gentamicin injections or labyrinthectomy due to variable outcomes - **Labyrinthectomy (Surgical Vestibular Ablation):** - **Goal:** Surgically destroy the vestibular apparatus - **Procedure:** Removal of the membranous labyrinth (transmastoid approach) or electrocoagulation of vestibular nerve and semicircular canals - **Efficacy:** 90–95% control of vertigo - **Major downside:** Permanent hearing loss and vestibular function loss in affected ear; vestibular rehabilitation required to compensate with other senses - **Indication:** Unilateral Ménière's with already poor hearing in affected ear, or when all other measures have failed - **Often reserved for older patients or those with severe disease** - **Vestibular nerve section:** - **Goal:** Surgically sever CN VIII (vestibular division) - **Procedure:** Retrolabyrinthine or translabyrinthine approach to identify and section the vestibular nerve fibers while preserving cochlear nerve (hearing) - **Efficacy:** 90–95% vertigo control - **Advantage:** Hearing may be preserved (if cochlear nerve spared) - **Disadvantage:** Complex neurosurgery; requires specialized expertise; risks include facial nerve injury, CSF leak, meningitis - **Indication:** Bilateral Ménière's or if hearing must be preserved; performed by neurotologic surgeons at tertiary centers **STEP 4: Vestibular Rehabilitation (Important Adjunct)** - **Goal:** Improve balance and reduce dizziness through retraining of vestibular and proprioceptive systems - **Beneficial for:** Residual imbalance between attacks, post-ablative procedures, chronic mild dizziness - **Techniques:** Cawthorne-Cooksey exercises, gaze stabilization, balance training - **Duration:** Several weeks to months; often requires physical therapist specializing in vestibular rehabilitation **Clinical Course and Prognosis** - **Highly variable:** Some patients have frequent attacks initially then spontaneous remission; others have chronic progressive disease - **Natural history:** After initial onset, frequency of attacks may increase over months to a few years, then stabilize or decrease in later decades - **Unilateral to bilateral conversion:** 15–30% of patients develop symptoms in the contralateral ear over 5–10 years - **Hearing loss:** Progressive in 2/3 of patients; fluctuating early, then stabilizing; permanent hearing loss develops in most patients over 10–20 years - **Disability:** While vertigo attacks often improve or resolve spontaneously in later years, permanent sensorineural hearing loss remains, and tinnitus may persist **Nursing Management During Acute Attack** **PRIORITY: Safety During Vertigo** 1. **Bed rest:** Confine patient to bed; severe vertigo makes standing/walking impossible and dangerous (fall risk) 2. **Darkened, quiet room:** Minimize sensory input; light and noise exacerbate vertigo and nausea 3. **Head position:** Lie still; sudden head movements trigger or worsen vertigo; some patients find lying on the affected side reduces symptoms (anomalous result, but sometimes helpful) 4. **Prevent falls:** Side rails up, call bell within reach; assist to bathroom if necessary (use gait belt and two-person assist) 5. **Antiemetics and vestibular suppressants:** Administer as ordered; IV/IM preferred during acute attack if nausea/vomiting prevents oral intake 6. **IV access:** Establish IV line; may need hydration if vomiting or unable to eat/drink 7. **NPO or light diet:** Until nausea/vomiting resolves; then progress to bland diet as tolerated 8. **Reassurance:** Explain that the attack will resolve; vertigo is frightening but not dangerous; anxiety reduction helps 9. **Monitoring:** Check vital signs, neurologic status; watch for any red-flag symptoms (severe headache, focal deficits) that might suggest other pathology 10. **Documentation:** Record onset time, duration, intensity, associated symptoms, and response to treatment **Patient and Family Education** 1. **Nature of disease:** Explain that Ménière's disease is chronic but manageable; attacks are episodic and unpredictable; no cure, but symptoms can be controlled with lifestyle and medications 2. **Symptoms recognition:** - Vertigo will come on suddenly; lie down immediately - Tinnitus and hearing changes may precede an attack (aura-like) - Aural fullness may signal impending attack 3. **Preventing attacks:** - Adhere to low-sodium diet; limit caffeine, alcohol, and smoking - Take diuretics and preventive medications as prescribed - Manage stress through relaxation, yoga, adequate sleep - Maintain good hydration 4. **During an attack:** - Lie down immediately in a safe place - Keep eyes still; avoid looking around - Remain in a quiet, dark room - Do not drive or operate machinery - Take antiemetics and vestibular suppressants as needed - Allow the attack to pass; most last 1–3 hours 5. **Hearing and tinnitus:** - Hearing loss is progressive; audiograms should be monitored annually - Hearing aids may become necessary - Tinnitus management: background noise, tinnitus masker, or white-noise machine at night - Not all tinnitus treatments are effective; trial and adjustment necessary 6. **Activities:** - Avoid activities with fall risk when possible (heights, water) - Plan ahead; know where medical help is available if attack occurs - Inform employers, family, and friends so they understand limitations during attacks - Some patients may need to adjust work schedules or seek disability accommodations 7. **Medication compliance:** - Take preventive medications consistently, even if no recent attacks - Never stop preventive medication abruptly without consulting physician - Report side effects; medication adjustment may help 8. **Support and coping:** - Connect with support groups (Ménière's disease associations exist in many countries) - Psychologic support may help with anxiety, depression, or adjustment to chronic illness - Address fear of attacks through counseling 9. **In the Philippine context:** - Emphasize the importance of regular ENT follow-up and audiometry at accredited centers - Discuss work accommodations if the patient works in occupations requiring balance or hearing (e.g., driver, factory worker with loud noise) - Educate on accessible ear centers and support resources available in the Philippines - For patients with severe disease, encourage referral to tertiary centers (hospitals with neurotologic services) if procedural intervention is considered